YK012治疗原发性膜性肾病的I期研究
YK012(一种人源化CD19×CD3双特异性抗体)在极高风险、难治性原发性膜性肾病患者中的I期研究
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics(PK), pharmacodynamics (PD), immunogenicity, and preliminary efficacy of YK012 in participants with primary membranous nephropathy (pMN).
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名:Minghui Zhao, M.D.
- 电话号码:+86-010-83572388
- 邮箱:mhzhao@bjmu.edu.cn
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Age 18-80 (inclusive), both gender.
- Diagnosed with primary (idiopathic) membranous nephropathy by renal biopsy within 10 years.
- Participants who meet the criteria of very high-risk primary (idiopathic) membranous nephropathy based on 2021 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Glomerular Diseases and who have failed available therapies for the treatment of pMN.
- eGFR estimated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula is ≥45 mL/min/1.73 m².
- If taking angiotensin-converting enzyme inhibitor (ACEI), angiotensin II receptor blocker (ARB), or Sodium-Glucose Co-Transporter 2 (SGLT-2) inhibitor, the medication dosage must have been stable (≤50% change in dose) for at least 4 weeks prior to screening and continue being stable prior to the initiation of the investigational product.
- Laboratory tests within 7 days prior to enrollment meet the pre-defined criteria.
- Be able to understand and voluntarily participate in this clinical trial with written signed informed consent and available for scheduled visits, treatments, examinations, and other study procedures.
Exclusion Criteria:
- Diagnosed with secondary membranous nephropathy.
- Any prior receipt of protocol-specified pharmacological treatment for membranous nephropathy.
- History of malignant tumor within 5 years prior to screening.
- Poorly controlled hypertension.
- Participants with severe renal insufficiency who have received or require dialysis or kidney transplantation within 6 months prior to the initiation of the investigational product.
- History of diabetic nephropathy confirmed by renal biopsy.
- History of severe or chronic infections within 6 months prior to screening or currently infection requiring systemic antibiotic or antiviral therapy.
- History of cardiovascular event leading to hospitalization within 6 months prior to screening.
- Other severe or poorly controlled diseases that may affect the protocol compliance or efficacy assessments.
- Have active tuberculosis with clear evidence of infection.
- History of substantial organ or bone marrow transplantation.
- Received live vaccination, underwent major surgery, or participated in other clinical trials and applied any other study drugs within 28 days prior to the initiation of the investigational product.
- Hepatitis B surface antigen (HBsAg) positive, or hepatitis B core antibody (HBcAb) positive with hepatitis B virus (HBV) DNA quantification ≥ 1×103 copies/L or ≥ 50 IU/L (HBcAb positive participants require regular HBV DNA testing); Hepatitis C virus (HCV) antibody positive; Human immunodeficiency virus (HIV) seropositive; Syphilis helical antibody positive.
- Peripheral blood CD4+ T-lymphocyte count < 200 cells/μL.
- The peripheral blood B-cell count is below the lower limit of normal.
- Known hypersensitivity to any of the ingredients of YK012.
- Female participants who are pregnant or breastfeeding, or women of childbearing potential (WOCBP) who have a positive pregnancy test result at screening; or those who plan to have children during the trial period and for 12 months after the end of the trial, and those who are unwilling to use one or more physical contraceptive methods during the trial period and for 12 months after the end of the trial.
- Other conditions that the investigator considers inappropriate for participation in this trial.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:顺序分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Ia: YK012
Participants with primary membranous nephropathy will receive ascending doses of YK012 infusion to evaluate the safety and tolerability of YK012, and to determine the Maximum Tolerated Dose (MTD) and Recommended Dose for Expansion (RDE) |
YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells |
|
实验性的:Ib: YK012
Participants will receive 2 different doses of YK012 infusion to evaluate the safety and tolerability of YK012 in participants with primary membranous nephropathy and to establish the Recommended Phase II Dose (RP2D). |
YK012 is a bispecific antibody targeting CD19 on B cells and CD3 on T cells leading to T cell-mediated cytotoxicity of malignant B cells |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Ia:剂量限制性毒性(DLT)
大体时间:首剂给药后最多28天内
|
首剂给药后最多28天内
|
|
不良事件 (AE)
大体时间:从首次诱导治疗至试验结束(第53周)
|
从首次诱导治疗至试验结束(第53周)
|
|
严重不良事件
大体时间:从首次诱导至试验结束(第53周)
|
从首次诱导至试验结束(第53周)
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
浓度-时间曲线下面积 (AUC0-t)
大体时间:从首次输注YK012前1小时至试验结束(第53周或第77周)
|
从首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
从时间0到无穷大的浓度-时间曲线下面积 (AUC0-∞)
大体时间:自首次输注YK012前1小时至试验结束(第53周或第77周)
|
自首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
最大血浆浓度(Cmax)
大体时间:从首次输注YK012前1小时至试验结束(第53周或第77周)
|
从首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
达到最大浓度的时间(Tmax)
大体时间:从首次输注YK012前1小时至试验结束(第53周或第77周)
|
从首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
半衰期 (t1/2)
大体时间:从首次输注YK012前1小时至试验结束(第53周或第77周)
|
从首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
表观清除率 (CL)
大体时间:从首次输注YK012前1小时至试验结束(第53周或第77周)
|
从首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
表观分布容积 (Vd)
大体时间:从首次输注YK012前1小时至试验结束(第53周或第77周)
|
从首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
最低血浆浓度 (Cmin)
大体时间:从首次输注YK012前1小时至试验结束(第53周或第77周)
|
从首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
外周血B细胞及B细胞亚群耗竭的起效时间与持续时间
大体时间:从YK012首次输注前1小时至试验结束(第53或77周)
|
从YK012首次输注前1小时至试验结束(第53或77周)
|
|
外周血自然杀伤(NK)细胞的变化
大体时间:从首次输注YK012前1小时至试验结束(第53周或第77周)
|
从首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
外周血T细胞及T细胞亚群(CD4+ T细胞、CD8+ T细胞)的变化
大体时间:从首次输注YK012前1小时至试验结束(第53周或第77周)
|
从首次输注YK012前1小时至试验结束(第53周或第77周)
|
|
细胞因子变化谱
大体时间:从首次输注YK012前1小时至试验结束(第53周或77周)
|
从首次输注YK012前1小时至试验结束(第53周或77周)
|
|
血液抗药抗体(ADA)与中和抗体(Nab)阳性率
大体时间:从首次输注YK012前1小时至试验结束(第53周或77周)
|
从首次输注YK012前1小时至试验结束(第53周或77周)
|
|
试验期间24小时尿蛋白相对于基线的变化
大体时间:从筛选至试验结束(第53或77周)
|
从筛选至试验结束(第53或77周)
|
|
试验期间估算肾小球滤过率(eGFR)相对于基线的变化
大体时间:从筛查到试验结束(第53周或第77周)
|
从筛查到试验结束(第53周或第77周)
|
|
试验期间抗磷脂酶A2受体(PLA2R)抗体滴度相对基线的变化
大体时间:从筛选至试验结束(第53周或第77周)
|
从筛选至试验结束(第53周或第77周)
|
|
实现总体肾脏缓解(ORR)的受试者比例
大体时间:从筛查至试验结束(第53周或第77周)
|
从筛查至试验结束(第53周或第77周)
|
|
实现完全缓解(CR)和部分缓解(PR)的受试者比例
大体时间:从筛选至试验结束(第53周或第77周)
|
从筛选至试验结束(第53周或第77周)
|
|
实现免疫学缓解的参与者比例
大体时间:从筛选到试验结束(第53周或第77周)
|
从筛选到试验结束(第53周或第77周)
|
|
达到完全缓解的时间
大体时间:从筛选至试验结束(53周或77周)
|
从筛选至试验结束(53周或77周)
|
|
达到客观缓解率的时间
大体时间:从筛选到试验结束(第53周或77周)
|
从筛选到试验结束(第53周或77周)
|
|
完全缓解持续时间
大体时间:从筛选到试验结束(第53周或第77周)
|
从筛选到试验结束(第53周或第77周)
|
|
客观缓解持续时间
大体时间:从筛选至试验结束,共53或77周
|
从筛选至试验结束,共53或77周
|
|
治疗失败参与者比例
大体时间:从筛查到试验结束(53周或77周)
|
从筛查到试验结束(53周或77周)
|
|
复发受试者比例
大体时间:从筛选到试验结束(53或77周)
|
从筛选到试验结束(53或77周)
|
合作者和调查者
调查人员
- 首席研究员:Minghui Zhao、Peking University First Hospital
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- YK012-3-FDA
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.